Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)
|出版商||Mordor Intelligence Pvt Ltd||商品編碼||704957|
|出版日期||內容資訊||英文 115 Pages
|全球裘馨氏肌肉萎縮症(DMD)治療市場:各治療方法、治療類型、終端用戶、地區(2018年∼2023年) Duchenne Muscular Dystrophy Treatment Market - Growth, Trends, and Forecast (2020 - 2025)|
|出版日期: 2020年06月01日||內容資訊: 英文 115 Pages||
The propelling factors for the growth of the Duchenne muscular dystrophy (DMD) treatment market include the rising disease burden of Duchenne muscular dystrophy, increasing investments in biopharmaceutical R&D to release novel disease therapies, and increasing awareness campaigns for DMD.
Currently, there is an increase in the number of clinical trials for testing the future treatment for Duchenne muscular dystrophy. The only accepted pharmacological therapy for the treatment of DMD is corticosteroid-based anti-inflammatory treatment. The pharmaceutical drug discovery and development have also grown rapidly in the past few years. As there have been great breakthroughs in technology in the last few years that may facilitate research processes and as the explosion of science in understanding the causes of diseases has made target selection more rational than ever, almost all major companies are now concentrating on R&D, which is likely to have a major impact on the market in the coming years.
Furthermore, with increasing awareness among people and with the government's urgency for the treatment of the disease, there is a big opportunity for the companies to conduct their trails and for new drugs launches, due to which, the market is expected to grow in the coming years.
Exon-skipping Segment is Expected to Dominate Duchenne Muscular Dystrophy Treatment Market
Duchenne muscular dystrophy is mostly caused by the internal deletions in the gene for dystrophin, a protein essential for maintaining muscle cell membrane integrity. One of the potential therapeutic method is to mask an exon close to the site where the others are missing, so that the remaining exons can join together. Exon-skipping approach signifies one of the most capable therapeutic approaches that aim to restore the expression of a shorter but functional dystrophin protein.
Moreover, market players are focusing on frequent launches in exon skipping technology which is a significant factor driving the segment thereby propelling the market growth. For instance, In December 2019, Sarepta's exon skipping drug, VYONDYS 53 (golodirsen) has been approved by the Food and Drug Administration (FDA) for the treatment of Duchenne muscular dystrophy.
North American Region holds the Largest Market Share and is Believed to Follow the Same Trend Over the Forecast Period
North America dominates the global Duchenne muscular dystrophy market, due to new product innovations, high healthcare expenditure, and government awareness programs. The United States has dominated the regional market and is projected to maintain its lead, owing to the rising disease incidence and anticipated launch of promising pipeline candidates. In addition, the market is expected to grow with increasing clinical trials around the world, especially in the United States and Europe. According to the FDA in 2017, the Emflaza (deflazacort) tablets and oral suspension were approved to treat DMD patients aged 5 years and above. Emflaza is a corticosteroid that works by decreasing inflammation and reducing the activity of the immune system.
With increasing campaigns and awareness programs, the number of patients is expected to come down, and hence, many companies are conducting campaign programs that help to improve focus on medicines for DMD treatment. There are also very few companies for new drug research for rare diseases because it needs bigger funds. Therefore, the market is not well established in many other therapeutic areas. However, it is expected to experience high growth and expand during the forecast period.